-
Qian Wei, Chief Commercial Officer of Junshi Biotechnology, resigns
Time of Update: 2021-11-14
On November 3, Junshi Biotech formally announced to its employees that the chief commercial officer Qian Wei has recently resigned to the company due to personal development reasons.
-
The first Sino-German Traditional Chinese Medicine Conference was held in Guangzhou to focus on the anti-epidemic effects of Chinese medicine
Time of Update: 2021-11-14
Photo by Chen Jimin China News Service, Guangzhou, November 4 (Cai Minjie, Cha Guanlin) The first Sino-German Traditional Chinese Medicine Conference was held in Guangzhou on the 4th.
-
Genxi Biotech will announce the results of preclinical research on the treatment of B-cell malignant tumors based on the CD19/CD7 dual-targeting allogeneic CAR-T candidate product (GC502) developed by TruUCAR at the 63rd ASH Annual Meeting
Time of Update: 2021-11-14
Suzhou, Shanghai, China and Palo Alto, California, USA November 4, 2021/PRNewswire/ - Genxi Biotech Group (NASDAQ: GRCL; referred to as "Genxi Bio") is committed to A global clinical-stage biopharmace
-
[FDA] The first C5aR inhibitor comes out!
Time of Update: 2021-11-14
S. FDA announced the approval of ChemoCentryx's oral selective complement 5a receptor (C5aR) inhibitor Tavneos (avacopan) to be marketed, combined with standard therapies to treat severely active antineutrophil cytoplasmic autoantibodies (ANCA) ) Related vasculitis, including granulomatous polyangiitis (GPA) and microscopic polyangiitis (MPA) .
-
Announcement of the State Food and Drug Administration on the conversion of aloe pearl capsule prescription drugs to over-the-counter drugs (No. 115 of 2021)
Time of Update: 2021-11-14
The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents .
Variety of non-prescription drug instructions template State Drug Administration September 23, 2021 State Drug Administration Announcement No.
-
TOP10 failed clinical studies in October 2021
Time of Update: 2021-11-14
Phase III study of Canakinumab in the treatment of non-small cell lung cancerNovartis announced on October 25 that the IL-1β inhibitor Canakinumab (canakinumab, ACZ885) combined with pembrolizumab plus platinum dual-drug chemotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) The phase III clinical study (CANOPY-1) failed to achieve the primary endpoints of improving overall survival (OS) and progression-free survival (PFS) .
-
"4+7" Cardiovascular Drug Terminal Market Changes
Time of Update: 2021-11-14
Figure 4 The market share and price trend of losartan designated product regulations in the sample hospital market (2017-2021H1)Based on the PDB domestic sample hospital market data, the market share and price changes of the four product specifications of Irbesartan from 2017 to the first half of 2021 are calculated separately.
-
Announcement of the State Food and Drug Administration on the issuance of two supplementary inspection methods for the rosin acid check item in Xiaozhong tablets and the check item of rhubarb glycosides in compound gentian sodium bicarbonate tablets (
Time of Update: 2021-11-14
Supplementary inspection method for rhubarb glycosides inspection items in compound gentian sodium bicarbonate tablets National Medical Products Administration October 12, 2021 National Medical Products Administration 2021 Announcement No.
-
The peptide drug market in my country has further expanded, and these companies are worth recommending
Time of Update: 2021-11-14
As a domestic peptide drug company, Sino Bio has always established its brand with innovative peptide drug pharmaceutical research services and peptide product customized production services, based on the large-scale production and sales of raw materials .
-
Announcement of the State Food and Drug Administration on the conversion of compound Banlangen Granules into over-the-counter drugs (No. 58 of 2021)
Time of Update: 2021-11-14
The list of varieties (Annex 1) and the template of non-prescription drug instructions (Annex 2) are released together .
The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents .
-
Novartis' potential "first-in-class" complement inhibitor reaches phase 2 clinical endpoint
Time of Update: 2021-11-14
Today, Novartis announced that its potential "first-in-class" oral factor B inhibitor iptacopan (LNP023) has reached its primary clinical endpoint in a phase 2 clinical trial for the treatment of patients with C3 glomerulopathy (C3G).
-
Asia Pacific Pharmaceuticals Mosapride Citrate Granules Obtained Drug Registration Certificate
Time of Update: 2021-11-14
On November 4, Asia-Pacific Pharmaceuticals issued an announcement stating that the company had received the "Drug Registration Certificate" for the chemical mosapride citrate granules approved and issued by the National Medical Products Administration .
No other company has obtained the registration certificate of the drug granules.
-
National Health Commission: Promote the integration and sharing of resources to implement the functional positioning of county hospitals in the hierarchical diagnosis and treatment system
Time of Update: 2021-11-14
Original title: National Health Commission: Promote the integration and sharing of resources to implement the functional positioning of county hospitals in the hierarchical diagnosis and treatment system The General Office of the National Health Commission issued the "Thousand Counties Project" County Hospital Comprehensive Capacity Improvement Work Plan (2021-2025), striving to achieve the level of tertiary hospital medical service capacity in at least 1,000 county hospitals across the country by 2025.
-
2020 Chinese Hospitals and Chinese Medical Colleges Science and Technology Values (STEM) released
Time of Update: 2021-11-14
( Photo courtesy of the Chinese Academy of Medical Sciences) The picture shows Wang Chen interpreting and releasing the 2020 STEM values for Chinese hospitals/medical colleges .
-
Jinghua Pharmaceutical completed the sale of its subsidiary Wannianchang Pharmaceutical's equity
Time of Update: 2021-11-14
On November 4, Jinghua Pharmaceutical issued an announcement stating that it had recently completed the sale of equity in its subsidiary Wannianchang Pharmaceutical .
The equity transfer transaction has been completed, and Jinghua Pharmaceutical no longer holds the equity of Wannianchang Pharmaceutical .
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Ginkgo Damo Injection (No. 71 of 2021)
Time of Update: 2021-11-14
The marketing authorization holder of this product should submit a supplementary application for the revision of the insert in accordance with the requirements for the revision of the insert sheet of Ginkgo Damo injection in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations.
-
The place will carry out the purchase of low-value consumables with a quantity, and the product decline may be very substantial
Time of Update: 2021-11-14
The notice pointed out that after the implementation of the Internet, in addition to first aid and other clinical needs, low-value medical consumables and test reagents used by public medical and health institutions in the city must be purchased on the procurement platform.
-
Johnson & Johnson, U.S., etc. are all developing the first FcRn-targeted new drug. When will it arrive?
Time of Update: 2021-11-14
In addition, another important research direction in this field is to develop drugs to inhibit the binding of endogenous FcRn and IgG, thereby treating autoimmune diseases driven by autoantibody .
-
Shandong: 115 drugs have been transferred out of medical insurance today!
Time of Update: 2021-11-14
Recently, Shandong Province Public Resource Exchange Center issued the "Notice on the province basic medical insurance, industrial injury insurance and maternity insurance drug list additions drugs in 2021 transferred out of work" .
-
Innovative achievements have been transformed into market considerations, and 3 new pharmaceutical stocks have broken!
Time of Update: 2021-11-14
According to statistics, a total of 396 companies have landed on the A-share market in 2020, but none of them broke on the first day of listing, and as of the end of the year, only 22 companies had fallen below the issue price .
